Michael Papsidero, MD
Otolaryngology · Ashtabula, OHNPI 1891826764
Payments from drug & device makers
Across 51 payments — averaging $20.44 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Xeris Pharmaceuticals, Inc.$110
- Lilly USA, LLC$104
- Sanofi$101
- Corcept Therapeutics$77
- Amgen$77
- Novo Nordisk$57
- plus $515 from 18 others
What the payments were for
- Food & beverage$1,043100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Xeris Pharmaceuticals, Inc. | 5 | $110 |
| Lilly USA, LLC | 5 | $104 |
| Sanofi | 4 | $101 |
| Corcept Therapeutics | 3 | $77 |
| Amgen | 4 | $77 |
| Novo Nordisk | 4 | $57 |
| Ascendis Pharma Endocrinology Inc | 2 | $50 |
| Acclarent, Inc | 2 | $49 |
| Abbott | 2 | $48 |
| Smith+Nephew | 2 | $45 |
| Medtronic | 2 | $42 |
| KARL Storz Endoscopy-america | 2 | $34 |
| Merck | 2 | $32 |
| GRT US Holding, Inc. | 1 | $27 |
| Boehringer Ingelheim | 1 | $23 |
| Greer Laboratories, Inc. | 1 | $22 |
| Antares Pharma, Inc. | 1 | $20 |
| Novartis | 1 | $20 |
| Clarus Therapeutics Inc. | 2 | $20 |
| Genentech USA, Inc. | 1 | $20 |
| Optinose US, Inc. | 1 | $19 |
| Rayner Intraocular Lenses Limited | 1 | $19 |
| Ascensia Diabetes Care US Inc. | 1 | $14 |
| Insulet Corporation | 1 | $12 |
How this compares
$1,043 in reported general payments places this provider in the 45th percentile of 380 otolaryngology providers in Ohio.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| RagwitekWeed Pollen-Short Ragweed | 12 | $3,683 |
| Neomycin-Polymyxin-HcNeomycin/Polymyxin B/Hydrocort | 23 | $921 |
| Ipratropium Bromide | 37 | $842 |
| Famotidine | 84 | $819 |
| Prednisolone Acetate | 26 | $805 |
| CefuroximeCefuroxime Axetil | 29 | $737 |
| Triamcinolone Acetonide | 20 | $713 |
| Fluticasone Propionate | 72 | $519 |
| Omeprazole | 98 | $467 |
| Methylprednisolone | 38 | $258 |
| Meclizine Hcl | 13 | $186 |
| Hydrocodone-AcetaminophenHydrocodone/Acetaminophen | 20 | $111 |
| Azithromycin | 15 | $70 |
| Levocetirizine Dihydrochloride | 12 | $36 |
Paid to pharmacies, not to this prescriber.
Other otolaryngology in Ashtabula
- Oliver AdunkaColumbus$1M
- Raj SindwaniCleveland$626K
- Mark MehleCleveland$403K
- Cameron WickCleveland$401K
- Troy WoodardCleveland$392K
- Ahmad SedaghatCincinnati$270K
- Eugene ChioColumbus$247K
- Subinoy DasColumbus$142K
- Katie PhillipsCincinnati$137K
- Sanjeet RangarajanCleveland$113K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.